PERJETA® (pertuzumab) is a HER2/neu receptor antagonist indicated for:
Use in combination with trastuzumab and docetaxel as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on demonstration of an improvement in pathological complete response rate. No data are available demonstrating improvement in event-free survival or overall survival.
Limitations of Use:

  • The safety of PERJETA as part of a doxorubicin-containing regimen has not been established
  • The safety of PERJETA administered for greater than 6 cycles for early breast cancer has not been established

Treatment of metastatic breast cancer in combination with Herceptin® (trastuzumab) and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

PERJETA and HER2+ breast cancer

See how PERJETA targets HER2 receptors in HER2+ breast cancer.

Financial assistance for patients

Genentech has multiple programs that may help your patients receive financial assistance.

Request more information

Genentech Clinical Oncology Specialists are available to answer your questions about PERJETA.